This database contains 100 studies, archived under the term: "Germany"
Click here to filter this large number of results.
Cued recall and other cognitive tasks to facilitate dementia recognition in primary care
Objectives: To compare the accuracy of commonly used tasks with that of the Visual Association Test (VAT), a conceptually different test involving cued recall of pictorial stimuli, in the recognition of dementia within primary care.; Design: A cross-sectional diagnostic study of concurrent validity.; Setting: Twenty-nine German primary care practices.; Participants: Four hundred twenty-three individuals in […]
Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study
Hampel, Harald,
Ewers, Michael,
Bürger, Katharina,
Annas, Peter,
Mörtberg, Anette,
Bogstedt, Anna,
Frölich, Lutz,
Schröder, Johannes,
Schönknecht, Peter,
Riepe, Matthias W.,
Kraft, Inga,
Gasser, Thomas,
Leyhe, Thomas,
Möller, Hans-Jürgen,
Kurz, Alexander,
Basun, Hans
Objective: Lithium, a first-line drug for the treatment of bipolar depression, has recently been shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the phosphorylation of the tau protein. Since hyperphosphorylation of tau is a core pathological feature in Alzheimer’s disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in […]
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
Burns, Alistair,
Bernabei, Roberto,
Bullock, Roger,
Cruz Jentoft, Alfonso J.,
Frölich, Lutz,
Hock, Christoph,
Raivio, Minna,
Triau, Eric,
Vandewoude, Maurits,
Wimo, Anders,
Came, Elizabeth,
Van Baelen, Bart,
Hammond, Gerry L.,
van Oene, Joop C.,
Schwalen, Susanne
Background: The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer’s disease (AD). Here we report its efficacy in patients with severe AD.; Methods: Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing […]
Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies
Dukart, Juergen,
Mueller, Karsten,
Horstmann, Annette,
Vogt, Barbara,
Frisch, Stefan,
Barthel, Henryk,
Becker, Georg,
Möller, Harald E.,
Villringer, Arno,
Sabri, Osama,
Schroeter, Matthias L.
FDG-PET ([18F]fluorodeoxyglucose positron emission tomography) is frequently used to improve the differential diagnosis of dementia. However, a fundamental methodological issue of the reference area for the intensity normalization procedure is still unsolved. Here, we systematically compared the two most commonly used normalization methods to the cerebral and to the cerebellar metabolic rate for glucose with […]
Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia
Dukart, Juergen,
Mueller, Karsten,
Horstmann, Annette,
Barthel, Henryk,
Möller, Harald E.,
Villringer, Arno,
Sabri, Osama,
Schroeter, Matthias L.
Introduction: Various biomarkers have been reported in recent literature regarding imaging abnormalities in different types of dementia. These biomarkers have helped to significantly improve early detection and also differentiation of various dementia syndromes. In this study, we systematically applied whole-brain and region-of-interest (ROI) based support vector machine classification separately and on combined information from different […]
Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial
Thyrian, Jochen René,
Fiß, Thomas,
Dreier, Adina,
Böwing, Georgia,
Angelow, Aniela,
Lueke, Sven,
Teipel, Stefan,
Fleßa, Steffen,
Grabe, Hans Jörgen,
Freyberger, Harald Jürgen,
Hoffmann, Wolfgang
Background: The provision of appropriate medical and nursing care for people with dementia is a major challenge for the healthcare system in Germany. New models of healthcare provision need to be developed, tested and implemented on the population level. Trials in which collaborative care for dementia in the primary care setting were studied have demonstrated […]
Dementia care management: going new ways in ambulant dementia care within a GP-based randomized controlled intervention trial
Eichler, Tilly,
Thyrian, Jochen René,
Dreier, Adina,
Wucherer, Diana,
Kohler, Leonore,
Fiß, Thomas,
Böwing, Georgia,
Michalowsky, Bernhard,
Hoffmann, Wolfgang
Background: Increasing prevalence of dementia is a major challenge for the German healthcare system. The study DelpHi-MV (“Dementia: life- and person-centered help in Mecklenburg-Western Pomerania”) aims to implement and evaluate an innovative subsidiary support system for persons with dementia (PwDs) living at home and their caregivers.; Methods: DelpHi-MV is a GP-based cluster randomized controlled intervention […]
WHEDA study: effectiveness of occupational therapy at home for older people with dementia and their caregivers–the design of a pragmatic randomised controlled trial evaluating a Dutch programme in seven German centres
Voigt-Radloff, Sebastian,
Graff, Maud,
Leonhart, Rainer,
Schornstein, Katrin,
Vernooij-Dassen, Myrra,
Olde Rikkert, Marcel,
Huell, Michael
Background: A recent Dutch mono-centre randomised controlled trial has shown that occupational therapy improves daily functioning in dementia. The aim of this present study is to compare the effects of the Dutch community occupational therapy programme with a community occupational therapy consultation on daily functioning in older people with mild or moderate dementia and their […]
German adaptation of the Resources for Enhancing Alzheimer’s Caregiver Health II: study protocol of a single-centred, randomised controlled trial
Heinrich, Stephanie,
Berwig, Martin,
Simon, Anke,
Jänichen, Jenny,
Hallensleben, Nina,
Nickel, Witiko,
Hinz, Andreas,
Brähler, Elmar,
Gertz, Hermann-Josef
Background: Caring for a family member with dementia is extremely stressful, and contributes to psychiatric and physical illness among caregivers. Therefore, a comprehensive programme called Resources for Enhancing Alzheimer’s Caregiver Health II (REACH II) was developed in the United States to enhance the health of Alzheimer’s caregivers. REACH II causes a clear reduction of the […]